Inhibrx Biosciences, Inc. (INBX)
USD 13.12
(-1.65%)
USD 13.12
(-1.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 219.83 Million USD | 67.43% |
| 2022 | 131.29 Million USD | 56.88% |
| 2021 | 83.68 Million USD | 4.28% |
| 2020 | 80.25 Million USD | 51.97% |
| 2019 | 52.8 Million USD | 42.67% |
| 2018 | 37.01 Million USD | 33.73% |
| 2017 | 27.67 Million USD | 49.13% |
| 2016 | 18.56 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 73.46 Million USD | -18.03% |
| 2024 Q2 | 160.52 Million USD | 119.15% |
| 2023 Q4 | 89.62 Million USD | 95.07% |
| 2023 Q1 | 43.78 Million USD | 22.39% |
| 2023 Q3 | 45.94 Million USD | 11.06% |
| 2023 FY | 219.83 Million USD | 67.43% |
| 2023 Q2 | 41.36 Million USD | -5.51% |
| 2022 Q2 | 35.3 Million USD | 17.96% |
| 2022 Q1 | 29.93 Million USD | 34.59% |
| 2022 Q4 | 35.77 Million USD | 18.14% |
| 2022 FY | 131.29 Million USD | 56.88% |
| 2022 Q3 | 30.28 Million USD | -14.24% |
| 2021 Q4 | 22.24 Million USD | 4.37% |
| 2021 Q2 | 20.71 Million USD | 6.68% |
| 2021 Q1 | 19.42 Million USD | -2.32% |
| 2021 FY | 83.68 Million USD | 4.28% |
| 2021 Q3 | 21.3 Million USD | 2.85% |
| 2020 Q1 | 18.48 Million USD | 10.54% |
| 2020 Q4 | 19.88 Million USD | -7.02% |
| 2020 Q3 | 21.38 Million USD | 4.31% |
| 2020 Q2 | 20.5 Million USD | 10.92% |
| 2020 FY | 80.25 Million USD | 51.97% |
| 2019 Q1 | 10.64 Million USD | 0.0% |
| 2019 Q2 | 11.6 Million USD | 8.99% |
| 2019 Q4 | 16.72 Million USD | 20.81% |
| 2019 FY | 52.8 Million USD | 42.67% |
| 2019 Q3 | 13.84 Million USD | 19.31% |
| 2018 Q1 | 11.39 Million USD | 0.0% |
| 2018 FY | 37.01 Million USD | 33.73% |
| 2018 Q2 | 9.17 Million USD | -19.51% |
| 2017 FY | 27.67 Million USD | 49.13% |
| 2016 FY | 18.56 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 20.129% |
| Alkermes plc | 996.24 Million USD | 77.934% |
| Agenus Inc. | 78.18 Million USD | -181.174% |
| Aptorum Group Limited | 10.56 Thousand USD | -2080441.359% |
| Ardelyx, Inc. | 169.93 Million USD | -29.36% |
| Dyadic International, Inc. | 9.15 Million USD | -2301.806% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -887.867% |
| Lantern Pharma Inc. | 17.87 Million USD | -1129.641% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3165.476% |
| Novavax, Inc. | 779.12 Million USD | 71.785% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -171.187% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -167.446% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1032.064% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -642.518% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -313.787% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 42.225% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -804.404% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -480.501% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -614.406% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -159.491% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1159.266% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -30.512% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -571.955% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -37.577% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 87.788% |
| AlloVir, Inc. | 180.93 Million USD | -21.498% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 50.682% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -640.617% |
| Bicycle Therapeutics plc | 216.92 Million USD | -1.341% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -27.881% |
| ChromaDex Corporation | 56.37 Million USD | -289.915% |
| Chimerix, Inc. | 93.38 Million USD | -135.392% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1480.415% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -46.032% |
| CRISPR Therapeutics AG | 463.49 Million USD | 52.571% |
| Precision BioSciences, Inc. | 92.46 Million USD | -137.749% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 13.468% |
| Fortress Biotech, Inc. | 200.19 Million USD | -9.808% |
| Fortress Biotech, Inc. | 200.19 Million USD | -9.808% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -571.319% |
| ImmuCell Corporation | 9.61 Million USD | -2185.762% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -39.297% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1261.926% |
| Incyte Corporation | 1.19 Billion USD | 81.535% |
| Innoviva, Inc. | 132.15 Million USD | -66.344% |
| IO Biotech, Inc. | 91.44 Million USD | -140.401% |
| Jaguar Health, Inc. | 42.01 Million USD | -423.218% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -29.864% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -160.7% |
| ContextLogic Inc. | 387 Million USD | 43.196% |
| MiMedx Group, Inc. | 229.72 Million USD | 4.308% |
| MEI Pharma, Inc. | 34.78 Million USD | -531.968% |
| NextCure, Inc. | 67.63 Million USD | -225.014% |
| Onconetix, Inc. | 34.9 Million USD | -529.751% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1624.698% |
| Opthea Limited | 191.96 Million USD | -14.514% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -7889.213% |
| Vaxcyte, Inc. | 468.04 Million USD | 53.032% |
| PDS Biotechnology Corporation | 43.04 Million USD | -410.695% |
| Precigen, Inc. | 84.18 Million USD | -161.14% |
| Pharming Group N.V. | 225.49 Million USD | 2.511% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -30.986% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -202.938% |
| PureTech Health plc | 144.59 Million USD | -52.029% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -68.759% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 10.331% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -804.404% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 3.87% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -612.369% |
| Acelyrin, Inc. | 422.06 Million USD | 47.915% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1704801.505% |
| Summit Therapeutics Inc. | 87.68 Million USD | -150.701% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -493.109% |
| Senti Biosciences, Inc. | 94.7 Million USD | -132.121% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -77.924% |
| Elevation Oncology, Inc. | 45.44 Million USD | -383.728% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -645.97% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -5476.543% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -66.317% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -544.946% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2501.231% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -21.251% |
| Seer, Inc. | 110.49 Million USD | -98.959% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -211.4% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -135.168% |
| ESSA Pharma Inc. | 32.13 Million USD | -584.102% |
| GlycoMimetics, Inc. | 39.28 Million USD | -459.573% |
| GT Biopharma, Inc. | 13.57 Million USD | -1519.255% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -9.306% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 15.263% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -287.304% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -306.49% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2112.094% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 45.528% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1061.34% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -333.65% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 15.339% |
| Aptose Biosciences Inc. | 52.35 Million USD | -319.875% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1425.498% |
| Soligenix, Inc. | 7.79 Million USD | -2720.05% |
| Century Therapeutics, Inc. | 56.07 Million USD | -292.056% |
| Kura Oncology, Inc. | 165.8 Million USD | -32.584% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -91.98% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2542.505% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -8758.259% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -104.117% |
| Autolus Therapeutics plc | 196.72 Million USD | -11.744% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -159.671% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -88.771% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1034.138% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 31.678% |
| GRI Bio, Inc. | 11.33 Million USD | -1840.247% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -3015.637% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -67.562% |
| IGM Biosciences, Inc. | 265.59 Million USD | 17.23% |
| INmune Bio, Inc. | 29.89 Million USD | -635.316% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -27.398% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -445.29% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1275.712% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1296.495% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -254.005% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -104.451% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 20.263% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 27.076% |
| Verastem, Inc. | 92.08 Million USD | -138.728% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1125.431% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -18.363% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -81.069% |
| Histogen Inc. | 14.27 Million USD | -1440.289% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1269.816% |
| Surrozen, Inc. | 18.55 Million USD | -1085.067% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1373.885% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4218.66% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -268.39% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -757.137% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -367.664% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2780.054% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -23.406% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -353.745% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 10.275% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1330.573% |
| Apollomics, Inc. | 54.14 Million USD | -306.04% |
| Amarin Corporation plc | 272.35 Million USD | 19.286% |
| Mesoblast Limited | 5.9 Million USD | -3624.67% |
| Turnstone Biologics Corp. | 78.33 Million USD | -180.617% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 9.951% |
| Synaptogenix, Inc. | 8.31 Million USD | -2544.141% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1407.13% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 13.13% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -559.554% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2389.233% |
| Exelixis, Inc. | 1.58 Billion USD | 86.146% |
| Better Therapeutics, Inc. | 38.26 Million USD | -474.539% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 5.266% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 74.295% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1761.852% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2633.556% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -632.938% |
| Gritstone bio, Inc. | 148.37 Million USD | -48.159% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -219.237% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1243.686% |
| Avid Bioservices, Inc. | 25.99 Million USD | -745.63% |
| Insmed Incorporated | 949.26 Million USD | 76.842% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1301.102% |
| MediWound Ltd. | 18.86 Million USD | -1065.094% |
| OmniAb, Inc. | 83.89 Million USD | -162.03% |
| Alector, Inc. | 248.8 Million USD | 11.645% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 6.179% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -320.719% |
| Zai Lab Limited | 547.47 Million USD | 59.847% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 44.857% |
| Aura Biosciences, Inc. | 84.99 Million USD | -158.651% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 11.05% |
| Immunic, Inc. | 99.22 Million USD | -121.551% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -38.247% |
| Veracyte, Inc. | 357.93 Million USD | 38.583% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.562% |
| FibroGen, Inc. | 398.11 Million USD | 44.782% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1447.009% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3091.517% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2985.016% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 93.248% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -749.65% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 30.553% |
| TG Therapeutics, Inc. | 198.47 Million USD | -10.76% |
| Galecto, Inc. | 35.62 Million USD | -517.032% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -440.269% |
| Fortrea Holdings Inc. | 457.3 Million USD | 51.929% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -305.008% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -661.237% |
| XBiotech Inc. | 37.51 Million USD | -486.057% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -219.237% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -964.604% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -54.743% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -121.882% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -98.553% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 77.059% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -662.108% |
| Vaxxinity, Inc. | 56.05 Million USD | -292.196% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 48.953% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -885.417% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -98.283% |
| NexImmune, Inc. | 28.16 Million USD | -680.438% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -3874.545% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1128.615% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 92.192% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -763.467% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1776.503% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -73.01% |
| Ainos, Inc. | 12.95 Million USD | -1597.18% |
| Pluri Inc. | 22.48 Million USD | -877.891% |
| Prothena Corporation plc | 282.4 Million USD | 22.158% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -9.903% |
| Celularity Inc. | 215.05 Million USD | -2.219% |
| Rallybio Corporation | 78.93 Million USD | -178.506% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1024.91% |
| MeiraGTx Holdings plc | 151.07 Million USD | -45.508% |
| Omeros Corporation | 94.75 Million USD | -132.008% |
| Humacyte, Inc. | 23.49 Million USD | -835.566% |
| Immunocore Holdings plc | 308.04 Million USD | 28.636% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -6384.661% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -153.071% |
| Blueprint Medicines Corporation | 722.86 Million USD | 69.589% |
| CalciMedica, Inc. | 21.81 Million USD | -907.609% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -194.441% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -36.932% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -28.334% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 25.466% |
| Pulmatrix, Inc. | 22.03 Million USD | -897.504% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -535.806% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -147.372% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 60.144% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -203.001% |
| Cytokinetics, Incorporated | 173.61 Million USD | -26.621% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -538.688% |
| Nutriband Inc. | 5.73 Million USD | -3733.778% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -404.047% |
| Vor Biopharma Inc. | 126.03 Million USD | -74.418% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 81.514% |
| Evogene Ltd. | 27.79 Million USD | -691.04% |
| ProKidney Corp. | 151.52 Million USD | -45.081% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -196.367% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2757.814% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 64.21% |
| CorMedix Inc. | 48.95 Million USD | -349.019% |
| BioLineRx Ltd. | 50.8 Million USD | -332.719% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -45.873% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -477.406% |
| Atai Life Sciences N.V. | 125.78 Million USD | -74.766% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -169.27% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -170.032% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 12.957% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -571.442% |
| MediciNova, Inc. | 10.9 Million USD | -1916.74% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -70.649% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2928.16% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3550.343% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 53.852% |
| Biomea Fusion, Inc. | 126.13 Million USD | -74.282% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 83.243% |
| Mereo BioPharma Group plc | 35.84 Million USD | -513.331% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -15.041% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 4.403% |
| Absci Corporation | 73.66 Million USD | -198.414% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -697.005% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -64.556% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 9.222% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 16.111% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -5.691% |
| Allakos Inc. | 196.05 Million USD | -12.126% |
| Imunon, Inc. | 20.31 Million USD | -982.351% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -93.736% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 40.363% |
| BioAtla, Inc. | 129.68 Million USD | -69.508% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1761.852% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1287.553% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -158.873% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -426.438% |
| XOMA Corporation | 46.46 Million USD | -373.129% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -97.74% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -54.307% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1593.736% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -112.076% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -27.165% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 13.712% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -487.655% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2572.766% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1208.045% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -9567.234% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 26.556% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3167.036% |
| UroGen Pharma Ltd. | 138.88 Million USD | -58.279% |
| Sutro Biopharma, Inc. | 243 Million USD | 9.538% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2921.875% |
| Orgenesis Inc. | 45.75 Million USD | -380.429% |
| Entera Bio Ltd. | 8.86 Million USD | -2381.151% |
| GH Research PLC | 41.22 Million USD | -433.283% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -755.103% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -164.686% |
| Xencor, Inc. | 306.97 Million USD | 28.389% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -4355.767% |
| Replimune Group, Inc. | 234.77 Million USD | 6.365% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -972.871% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -14.617% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3167.036% |
| Portage Biotech Inc. | 18.19 Million USD | -1107.924% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2928.16% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -109.44% |
| OncoCyte Corporation | 25.63 Million USD | -757.472% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3506.368% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1818.729% |
| Purple Biotech Ltd. | -22.46 Million USD | 1078.457% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1233.92% |
| scPharmaceuticals Inc. | 65.17 Million USD | -237.276% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2500.696% |
| HilleVax, Inc. | 133.34 Million USD | -64.858% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2037.385% |
| Tharimmune, Inc. | 9.45 Million USD | -2224.959% |
| Genprex, Inc. | 31.06 Million USD | -607.746% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -17.226% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -600.609% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -28635.948% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -3935.86% |
| OKYO Pharma Limited | 8243.57 USD | -2666584.458% |
| Savara Inc. | 15.74 Million USD | -1296.189% |
| Curis, Inc. | 58.35 Million USD | -276.712% |
| Daré Bioscience, Inc. | 33.6 Million USD | -554.073% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -4216.75% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2846.388% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -713.522% |
| BeiGene, Ltd. | 3.28 Billion USD | 93.311% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1002.496% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 55.925% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -43.07% |
| Erasca, Inc. | 141.52 Million USD | -55.329% |
| bluebird bio, Inc. | 240.23 Million USD | 8.493% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4756.003% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 87.411% |
| DBV Technologies S.A. | 92.16 Million USD | -138.531% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4756.003% |
| Moderna, Inc. | 6.39 Billion USD | 96.562% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -415.924% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1430.21% |
| Molecular Templates, Inc. | 63.09 Million USD | -248.433% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -229.575% |
| Travere Therapeutics, Inc. | 472 Million USD | 53.426% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -53.394% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -254.096% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -406.357% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -5.621% |
| MacroGenics, Inc. | 217.21 Million USD | -1.204% |
| RenovoRx, Inc. | 11.39 Million USD | -1829.01% |
| Adicet Bio, Inc. | 152.03 Million USD | -44.589% |
| Prime Medicine, Inc. | 186.63 Million USD | -17.784% |
| Aditxt, Inc. | 25.95 Million USD | -747.104% |
| Adagene Inc. | 41.83 Million USD | -425.515% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2907.21% |
| Quantum-Si incorporated | 111.65 Million USD | -96.876% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -27.92% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1407.981% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -513.673% |
| SciSparc Ltd. | 9.01 Million USD | -2339.574% |
| Vericel Corporation | 142.04 Million USD | -54.766% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2439.431% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -852.115% |
| Generation Bio Co. | 144.46 Million USD | -52.166% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -164.76% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -154.256% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 25.663% |
| Invivyd, Inc. | 205.75 Million USD | -6.841% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -204.647% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2243.977% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -192.117% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2036.969% |
| 2seventy bio, Inc. | 289.88 Million USD | 24.167% |
| ADMA Biologics, Inc. | 66.58 Million USD | -230.144% |
| Clene Inc. | 41.07 Million USD | -435.218% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1616.364% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -301.179% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3550.343% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 37.557% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -498.47% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -551.773% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -111.982% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -574.553% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -29.101% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 71.366% |
| Evaxion Biotech A/S | 22.27 Million USD | -887.113% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -62.183% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 6.408% |
| Trevena, Inc. | 38.41 Million USD | -472.28% |
| Surrozen, Inc. | 18.55 Million USD | -1085.067% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -174.977% |
| Cingulate Inc. | 22.75 Million USD | -865.896% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 3034.196% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -392.153% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2569.803% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -114.347% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 70.848% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -254.142% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2414.829% |
| Kronos Bio, Inc. | 128.11 Million USD | -71.584% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -161.478% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7395.095% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -118.027% |
| Statera Biopharma, Inc. | 28.82 Million USD | -662.517% |
| ImmunityBio, Inc. | 362.87 Million USD | 39.419% |
| Korro Bio, Inc. | 84.53 Million USD | -160.049% |
| Kineta, Inc. | 21.15 Million USD | -939.091% |
| BioVie Inc. | 31.95 Million USD | -588.039% |
| Codexis, Inc. | 66.51 Million USD | -230.482% |
| Celularity Inc. | 215.05 Million USD | -2.219% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 2.997% |
| Celcuity Inc. | 66.23 Million USD | -231.917% |
| Virax Biolabs Group Limited | 6.54 Million USD | -3257.689% |
| Cibus, Inc. | 320.3 Million USD | 31.369% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -411.233% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -549.539% |
| IN8bio, Inc. | 30.33 Million USD | -624.627% |
| Kodiak Sciences Inc. | 277.32 Million USD | 20.731% |
| Annexon, Inc. | 143.72 Million USD | -52.954% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -72.293% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -859.579% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -34248.438% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 71.802% |
| Eyenovia, Inc. | 25.4 Million USD | -765.253% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -56.669% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3852.355% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -177.798% |
| Arcellx, Inc. | 200.19 Million USD | -9.806% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -378.932% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -1.58% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2107.794% |
| Moolec Science SA | 52.75 Million USD | -316.735% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -259.564% |
| Geron Corporation | 70.44 Million USD | -212.077% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -372.346% |
| Royalty Pharma plc | 862.4 Million USD | 74.51% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -133.683% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2256.702% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -871.473% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -5.783% |
| Humacyte, Inc. | 23.49 Million USD | -835.566% |
| Structure Therapeutics Inc. | 102.77 Million USD | -113.894% |
| 89bio, Inc. | 151.2 Million USD | -45.386% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -174.335% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1411.898% |
| Genelux Corporation | 24.33 Million USD | -803.349% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -548.026% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -27.166% |
| Notable Labs, Ltd. | 14.77 Million USD | -1388.355% |
| Liquidia Corporation | 87.98 Million USD | -149.852% |
| Mustang Bio, Inc. | 48.5 Million USD | -353.248% |
| Immunovant, Inc. | 282.7 Million USD | 22.242% |
| Quantum-Si incorporated | 111.65 Million USD | -96.876% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -875.115% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -933.667% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -115.494% |
| Acasti Pharma Inc. | 11.3 Million USD | -1845.226% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -859.072% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1275.712% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -372.326% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -19275.452% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1283.797% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -653.953% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -431.196% |
| PepGen Inc. | 84.76 Million USD | -159.337% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -641.892% |
| United Therapeutics Corporation | 885.1 Million USD | 75.163% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -860.082% |
| Solid Biosciences Inc. | 104.31 Million USD | -110.737% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -571.738% |
| Immuneering Corporation | 58.41 Million USD | -276.338% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4218.66% |
| Silo Pharma, Inc. | 3.92 Million USD | -5505.254% |
| Belite Bio, Inc | 31.66 Million USD | -594.171% |
| XOMA Corporation | 46.46 Million USD | -373.129% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -225.433% |
| Bionomics Limited | 17.89 Billion USD | 98.771% |
| Apogee Therapeutics, Inc. | 93 Million USD | -136.369% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 716.115% |
| uniQure N.V. | 285.08 Million USD | 22.89% |
| Cassava Sciences, Inc. | 105.95 Million USD | -107.471% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2907.21% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -13.194% |
| Forte Biosciences, Inc. | 32.47 Million USD | -576.879% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2545.763% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -647.848% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3852.355% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1447.009% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2373.057% |
| Altimmune, Inc. | 30.55 Million USD | -619.433% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 48.596% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 716.115% |
| Compugen Ltd. | 43.97 Million USD | -399.943% |
| Peak Bio, Inc. | 1249.13 USD | -17598548.659% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -196.587% |
| Benitec Biopharma Inc. | 22.38 Million USD | -882.173% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 9.605% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -670.171% |
| Zura Bio Limited | 62.63 Million USD | -250.953% |
| PolyPid Ltd. | 21.04 Million USD | -944.571% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1250.639% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -670.171% |
| Instil Bio, Inc. | 85.78 Million USD | -156.257% |
| argenx SE | 1.53 Billion USD | 85.665% |
| Immunome, Inc. | 122.82 Million USD | -78.986% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -353.51% |
| Verona Pharma plc | 67.15 Million USD | -227.365% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -749.256% |
| Shattuck Labs, Inc. | 93.61 Million USD | -134.826% |
| CervoMed Inc. | 14.95 Million USD | -1369.671% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -210.92% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2472.917% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -331.039% |
| Moolec Science SA | 52.75 Million USD | -316.735% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1236.479% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -65.84% |
| AnaptysBio, Inc. | 181.56 Million USD | -21.073% |
| Design Therapeutics, Inc. | 78.19 Million USD | -181.148% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -152.559% |
| NeurAxis, Inc. | 8.82 Million USD | -2392.065% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1646.762% |
| Lumos Pharma, Inc. | 38.66 Million USD | -468.55% |
| Achilles Therapeutics plc | 75.25 Million USD | -192.113% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -749.256% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1531.089% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -729.471% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7395.095% |
| Nutriband Inc. | 5.73 Million USD | -3733.778% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -98.438% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -295.001% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -332.064% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -232.577% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -306.167% |
| Palisade Bio, Inc. | 13.32 Million USD | -1550.375% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -384.111% |
| Beam Therapeutics Inc. | 554.19 Million USD | 60.333% |
| Neurogene Inc. | 55.58 Million USD | -295.499% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 11.533% |
| AEON Biopharma, Inc. | 48.42 Million USD | -353.922% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -127.308% |
| Sesen Bio, Inc. | 78.38 Million USD | -180.463% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -163.178% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1646.499% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 51.256% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -150.119% |
| Athira Pharma, Inc. | 125.46 Million USD | -75.211% |
| Vaccinex, Inc. | 23.45 Million USD | -837.242% |
| HCW Biologics Inc. | 21.02 Million USD | -945.44% |
| XOMA Corporation | 46.46 Million USD | -373.129% |
| Nektar Therapeutics | 190.9 Million USD | -15.153% |
| Arvinas, Inc. | 480 Million USD | 54.202% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -9567.234% |
| Merus N.V. | 200.49 Million USD | -9.644% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -112.694% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -534.98% |
| Rezolute, Inc. | 70.38 Million USD | -212.316% |
| Clene Inc. | 41.07 Million USD | -435.218% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1242.189% |
| BeyondSpring Inc. | 24.86 Million USD | -784.094% |
| Synlogic, Inc. | 58.53 Million USD | -275.572% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1128.65% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -4793.811% |
| Peak Bio, Inc. | 1249.13 USD | -17598548.659% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -263.68% |
| Krystal Biotech, Inc. | 160.42 Million USD | -37.029% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 18.771% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 36.837% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -10092.727% |
| MannKind Corporation | 125.59 Million USD | -75.028% |
| Ikena Oncology, Inc. | 84.57 Million USD | -159.917% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2178.74% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -145.343% |
| Gossamer Bio, Inc. | 183.75 Million USD | -19.63% |
| CohBar, Inc. | 12.38 Million USD | -1674.497% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -333.385% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -697.005% |
| Legend Biotech Corporation | 583.14 Million USD | 62.303% |
| Mural Oncology plc | 192.07 Million USD | -14.452% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -227.386% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1261.575% |
| Disc Medicine, Inc. | 91.12 Million USD | -141.24% |
| Champions Oncology, Inc. | 28.11 Million USD | -682.035% |
| REGENXBIO Inc. | 321.15 Million USD | 31.551% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -4000.362% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -294.271% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -464.236% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -92.231% |
| Vaxart, Inc. | 90.72 Million USD | -142.301% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2480.162% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -413.693% |
| Cellectis S.A. | 97.32 Million USD | -125.884% |
| Longeveron Inc. | 21.25 Million USD | -934.494% |
| Repare Therapeutics Inc. | 167.35 Million USD | -31.354% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 83.846% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -190.607% |
| Revolution Medicines, Inc. | 498.76 Million USD | 55.925% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3204.72% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -400.137% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -194.718% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -215.689% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1887.613% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.396% |
| Denali Therapeutics Inc. | 527.23 Million USD | 58.305% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2439.431% |
| Veru Inc. | 101.34 Million USD | -116.906% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -839.163% |
| Cingulate Inc. | 22.75 Million USD | -865.896% |
| Passage Bio, Inc. | 108.38 Million USD | -102.816% |
| Context Therapeutics Inc. | 25.07 Million USD | -776.773% |
| Exicure, Inc. | 14.07 Million USD | -1461.736% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -6.68% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -407.679% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2295.369% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 12.933% |
| Nuvalent, Inc. | 149.49 Million USD | -47.051% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2625.086% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -112.089% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -924.896% |
| OmniAb, Inc. | 83.89 Million USD | -162.03% |
| Anew Medical, Inc. | 1.3 Million USD | -16799.068% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -570.95% |
| Lipocine Inc. | 15.08 Million USD | -1357.745% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -220.859% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -188.673% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -445.29% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -91.418% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -882.085% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 66.9% |
| Ocugen, Inc. | 71.56 Million USD | -207.167% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -134.196% |
| Q32 Bio Inc. | 92.68 Million USD | -137.192% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -938.207% |
| Alumis Inc. Common Stock | 158.17 Million USD | -38.98% |
| Equillium, Inc. | 50.6 Million USD | -334.395% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -252.258% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1480.879% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1065.273% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -368.212% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -102.672% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1673.863% |
| Dominari Holdings Inc. | 23.83 Million USD | -822.299% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2283.56% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1746.225% |
| Bio-Techne Corporation | 563.03 Million USD | 60.957% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 46.226% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 18.205% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -66.189% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1425.432% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -34.292% |
| Nkarta, Inc. | 131.65 Million USD | -66.981% |
| BioCardia, Inc. | 12.12 Million USD | -1713.629% |
| Iterum Therapeutics plc | 47.46 Million USD | -363.112% |